David C Montefiori
Overview
Explore the profile of David C Montefiori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
605
Citations
36312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shen X, Korber B, Spreng R, Sawant S, deCamp A, McMillan A, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006680
Background: HIV-1 envelope (Env) variable loops 1 and 2 (V1V2) directed non-neutralizing antibodies were a correlate of decreased transmission risk in the RV144 vaccine trial. Thus, the elicitation and breadth...
2.
Jamieson P, Shen X, Abu-Shmais A, Wasdin P, Janowska K, Edwards R, et al.
bioRxiv
. 2025 Feb;
PMID: 39896680
HIV-1 continues to pose a significant global health challenge, requiring ongoing research into effective prevention and treatment strategies. Understanding the B cell repertoire that can be engaged upon vaccination in...
3.
Wilson G, Church L, Kelley C, Robinson S, Lu Y, Furch B, et al.
J Infect Dis
. 2024 Dec;
PMID: 39671174
Utilizing transiently transfected cell lines could significantly reduce manufacturing timelines for protein subunit vaccines. This trial compared safety and immunogenicity of human immunodeficiency virus (HIV) envelope CH505TF gp120 vaccines produced...
4.
Edupuganti S, Hurt C, Stephenson K, Huang Y, Paez C, Yu C, et al.
Lancet HIV
. 2024 Dec;
12(1):e13-e25.
PMID: 39667379
Background: Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics...
5.
Holmes S, Li H, Shen X, Martin M, Tuck R, Chen Y, et al.
Nat Commun
. 2024 Nov;
15(1):10302.
PMID: 39604409
The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in...
6.
Brinkkemper M, Kerster G, Brouwer P, Tran A, Torres J, Ettema R, et al.
PLoS Pathog
. 2024 Oct;
20(10):e1012558.
PMID: 39361585
An effective human immunodeficiency virus 1 (HIV-1) vaccine will most likely have to elicit broadly neutralizing antibodies (bNAbs) to overcome the sequence diversity of the envelope glycoprotein (Env). So far,...
7.
Hahn W, Parks K, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, et al.
J Exp Med
. 2024 Sep;
221(10).
PMID: 39235529
Stabilized trimers preserving the native-like HIV envelope structure may be key components of a preventive HIV vaccine regimen to induce broadly neutralizing antibodies (bnAbs). We evaluated trimeric BG505 SOSIP.664 gp140...
8.
Nelson A, Shen X, Vekatayogi S, Zhang S, Ozorowski G, Dennis M, et al.
Sci Immunol
. 2024 Aug;
9(98):eadm7097.
PMID: 39213340
Adolescents are a growing population of people living with HIV. The period between weaning and sexual debut presents a low-risk window for HIV acquisition, making early childhood an ideal time...
9.
Caniels T, Medina-Ramirez M, Zhang S, Kratochvil S, Xian Y, Koo J, et al.
Sci Immunol
. 2024 Aug;
9(98):eadk9550.
PMID: 39213338
Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine development. Here, we describe how germline-targeting immunogen BG505 SOSIP germline trimer 1.1 (GT1.1), generated through structure-based...
10.
Zhang Q, Lindenberger J, Parsons R, Thakur B, Parks R, Park C, et al.
Mol Cell
. 2024 Jul;
84(14):2747-2764.e7.
PMID: 39059371
A recombinant lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant, named XBB, appeared in late 2022 and evolved descendants that successively swept local and global populations....